Phalanx Cabergoline 0.25mg

Description

Phalanx Cabergoline 0.25mg is the precision half-dose — ideal for those starting cabergoline therapy, managing low-to-moderate prolactin elevations, or fine-tuning an existing protocol. Cabergoline’s long half-life (60–69 hours) and high potency at dopamine D2 receptors mean small doses have substantial, sustained effects: 0.25mg twice weekly is the dose used in clinical hyperprolactinaemia trials and represents the minimum effective dose for most users. For cycle support on 19-nor-containing stacks, 0.25mg twice weekly provides meaningful prolactin control without the sedation and blood pressure effects seen at higher doses. This granularity also makes it the correct starting point for new users — establishing tolerability before increasing to 0.5mg if prolactin remains elevated. The dopaminergic effects also extend to mood, motivation, and sexual function, with users reporting improved libido and reduced anorgasmia at therapeutic doses. Every tablet independently verified at 99%+ purity by Puralytix. Blood prolactin testing is the gold standard for Cabergoline dosing — targeting prolactin in the low-normal range (5–15 ng/mL) on cycle confirms suppression without over-driving dopamine signalling. At 0.25mg twice weekly, the risk of excessive dopaminergic side effects (dizziness, blood pressure changes) is minimal, making this the safest entry point for new Cabergoline users.